Saccharomyces boulardii in maintenance treatment of Crohn’s disease

Saccharomyces boulardii in maintenance treatment of Crohn’s disease – Abstract

M Guslandi

Saccharomyces boulardii in maintenance treatment of Crohn’s disease.

Guslandi M, Mezzi G, Sorghi M, Testoni PA. Dig Dis Sci 2000;45:1462-1464.

The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn’s disease has been evaluated. Thirty-two patients with Crohn’s disease in clinical remission (CDAI [is less than] 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn’s disease. However, in view of the product’s cost, further controlled studies are needed to confirm these preliminary data.

COPYRIGHT 2000 Thorne Research Inc.

COPYRIGHT 2001 Gale Group